ES2904900T3 - Tirotricina para usar en el tratamiento o la profilaxis del olor corporal, así como sus composiciones - Google Patents
Tirotricina para usar en el tratamiento o la profilaxis del olor corporal, así como sus composiciones Download PDFInfo
- Publication number
- ES2904900T3 ES2904900T3 ES18740140T ES18740140T ES2904900T3 ES 2904900 T3 ES2904900 T3 ES 2904900T3 ES 18740140 T ES18740140 T ES 18740140T ES 18740140 T ES18740140 T ES 18740140T ES 2904900 T3 ES2904900 T3 ES 2904900T3
- Authority
- ES
- Spain
- Prior art keywords
- thyrothricin
- treatment
- composition
- body odor
- foot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 75
- 206010040904 Skin odour abnormal Diseases 0.000 title claims abstract description 73
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 117
- 208000035985 Body Odor Diseases 0.000 claims abstract description 78
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 239000002674 ointment Substances 0.000 claims description 25
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- 239000007921 spray Substances 0.000 claims description 19
- 239000003410 keratolytic agent Substances 0.000 claims description 18
- 206010052428 Wound Diseases 0.000 claims description 17
- 230000000699 topical effect Effects 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004202 carbamide Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- -1 roll-on preparation Substances 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000001530 keratinolytic effect Effects 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 229940124091 Keratolytic Drugs 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 208000034309 Bacterial disease carrier Diseases 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 230000001960 triggered effect Effects 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 2
- 229960005339 acitretin Drugs 0.000 claims description 2
- 229960002916 adapalene Drugs 0.000 claims description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 2
- 229960005280 isotretinoin Drugs 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229960005406 motretinide Drugs 0.000 claims description 2
- IYIYMCASGKQOCZ-DJRRULDNSA-N motretinide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C IYIYMCASGKQOCZ-DJRRULDNSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229910000338 selenium disulfide Inorganic materials 0.000 claims description 2
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005265 selenium sulfide Drugs 0.000 claims description 2
- 239000003079 shale oil Substances 0.000 claims description 2
- 239000011269 tar Substances 0.000 claims description 2
- 229960000565 tazarotene Drugs 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 57
- 210000002683 foot Anatomy 0.000 description 49
- 235000019645 odor Nutrition 0.000 description 26
- 241000282412 Homo Species 0.000 description 25
- 206010055000 Bromhidrosis Diseases 0.000 description 18
- 208000008454 Hyperhidrosis Diseases 0.000 description 17
- 230000037315 hyperhidrosis Effects 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- 210000004243 sweat Anatomy 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 9
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 8
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000002781 deodorant agent Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004013 groin Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000009965 odorless effect Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229940098458 powder spray Drugs 0.000 description 4
- 208000001126 Keratosis Diseases 0.000 description 3
- 208000034693 Laceration Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010069447 Pitted keratolysis Diseases 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 210000000106 sweat gland Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 241000195940 Bryophyta Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000036617 axillary hyperhidrosis Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006003 cornification Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical class [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 108010025899 gelatin film Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000036563 plantar hyperhidrosis Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 244000026610 Cynodon dactylon var. affinis Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010049096 Dysmorphophobia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241001464016 Pedum Species 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036773 apocrine secretion Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- DMRHOZBCVOAFHR-UHFFFAOYSA-N benzyl-[2-(2,6-dimethylanilino)-2-oxoethyl]-diethylazanium 1-oxido-1-oxo-1,2-benzothiazol-3-one Chemical compound CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C.C1=CC=C2C(=C1)C(=O)N=S2(=O)[O-] DMRHOZBCVOAFHR-UHFFFAOYSA-N 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MQBCDKMPXVYCGO-FQBKTPCVSA-N mycothiol Chemical compound CC(=O)N[C@@H](CS)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O MQBCDKMPXVYCGO-FQBKTPCVSA-N 0.000 description 1
- 108010074581 mycothiol Proteins 0.000 description 1
- MQBCDKMPXVYCGO-UHFFFAOYSA-N mycothiol Natural products CC(=O)NC(CS)C(=O)NC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(O)C1O MQBCDKMPXVYCGO-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Socks And Pantyhose (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017116407 | 2017-07-20 | ||
| PCT/EP2018/067991 WO2019015955A1 (de) | 2017-07-20 | 2018-07-03 | Tyrothricin zur anwendung bei der behandlung oder prophylaxe von körpergeruch sowie zubereitungen hierfür |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2904900T3 true ES2904900T3 (es) | 2022-04-06 |
Family
ID=62904430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18740140T Active ES2904900T3 (es) | 2017-07-20 | 2018-07-03 | Tirotricina para usar en el tratamiento o la profilaxis del olor corporal, así como sus composiciones |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20200139164A1 (enExample) |
| EP (1) | EP3654932B1 (enExample) |
| JP (1) | JP7292272B2 (enExample) |
| KR (1) | KR20200031673A (enExample) |
| CN (1) | CN111093611B (enExample) |
| AU (1) | AU2018302367B2 (enExample) |
| CA (1) | CA3070246A1 (enExample) |
| CY (1) | CY1124904T1 (enExample) |
| DK (1) | DK3654932T3 (enExample) |
| ES (1) | ES2904900T3 (enExample) |
| HR (1) | HRP20220034T1 (enExample) |
| HU (1) | HUE057646T2 (enExample) |
| LT (1) | LT3654932T (enExample) |
| MX (1) | MX2020000681A (enExample) |
| PL (1) | PL3654932T3 (enExample) |
| PT (1) | PT3654932T (enExample) |
| RS (1) | RS62825B1 (enExample) |
| RU (1) | RU2020107394A (enExample) |
| SI (1) | SI3654932T1 (enExample) |
| SM (1) | SMT202200149T1 (enExample) |
| WO (1) | WO2019015955A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119255706A (zh) * | 2022-05-13 | 2025-01-03 | 营养与生物科学美国第四公司 | 包含短芽孢杆菌属多功能发酵物的组合物及使用方法 |
| CN117717492B (zh) * | 2023-12-19 | 2024-08-20 | 中山自然说生物科技有限公司 | 一种修复腋窝微生态的生物制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3079299A (en) * | 1959-11-16 | 1963-02-26 | Gen Aerosol Corp | Self-propelling medicinal ointment composition containing polyethylene and method ofapplication |
| US3624200A (en) * | 1964-07-21 | 1971-11-30 | Upjohn Co | Controlling perspiration on human skin with scopolamine esters |
| IE37447B1 (en) | 1972-04-05 | 1977-07-20 | Procter & Gamble | Dermatological compositions |
| DE3604865A1 (de) | 1986-02-15 | 1987-08-20 | Walter Dr Med Langbehn | Haut-kosmetikum |
| JPH01313423A (ja) * | 1988-06-03 | 1989-12-18 | Biogal Gyogyszergyar | 耳炎用点耳薬の新規製薬組成物 |
| DE3827561C1 (enExample) | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| PL173704B1 (pl) * | 1992-10-28 | 1998-04-30 | Den Mat Corp | Bezalkoholowa, przeciwbakteryjna kompozycja do higieny jamy ustnej |
| DE4328871A1 (de) * | 1993-08-27 | 1995-03-02 | Beiersdorf Ag | Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis |
| DE19823318A1 (de) | 1998-05-26 | 1999-12-02 | Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg | Verwendung eines Arzneimittels mit einem Gehalt an Tyrothricin zur Behandlung von Virusinfektionen |
| US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| DE202005012644U1 (de) | 2005-08-08 | 2005-11-03 | S+S Separation And Sorting Technology Gmbh | Metallseparator |
| AU2014260509B2 (en) * | 2013-05-03 | 2019-08-01 | Emollivet Ab | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients |
| EP3215129A2 (en) * | 2014-11-04 | 2017-09-13 | invenres GmbH | Pharmaceutical preparation and method of its production and use |
| CN205682452U (zh) * | 2016-03-30 | 2016-11-16 | 武汉鑫大宸科技有限公司 | 纳米抗菌袜 |
-
2018
- 2018-07-03 SM SM20220149T patent/SMT202200149T1/it unknown
- 2018-07-03 RU RU2020107394A patent/RU2020107394A/ru unknown
- 2018-07-03 SI SI201830530T patent/SI3654932T1/sl unknown
- 2018-07-03 PT PT187401401T patent/PT3654932T/pt unknown
- 2018-07-03 WO PCT/EP2018/067991 patent/WO2019015955A1/de not_active Ceased
- 2018-07-03 AU AU2018302367A patent/AU2018302367B2/en active Active
- 2018-07-03 HU HUE18740140A patent/HUE057646T2/hu unknown
- 2018-07-03 ES ES18740140T patent/ES2904900T3/es active Active
- 2018-07-03 MX MX2020000681A patent/MX2020000681A/es unknown
- 2018-07-03 CN CN201880057627.7A patent/CN111093611B/zh active Active
- 2018-07-03 US US16/632,700 patent/US20200139164A1/en not_active Abandoned
- 2018-07-03 DK DK18740140.1T patent/DK3654932T3/da active
- 2018-07-03 JP JP2020524673A patent/JP7292272B2/ja active Active
- 2018-07-03 EP EP18740140.1A patent/EP3654932B1/de active Active
- 2018-07-03 CA CA3070246A patent/CA3070246A1/en active Pending
- 2018-07-03 LT LTEPPCT/EP2018/067991T patent/LT3654932T/lt unknown
- 2018-07-03 KR KR1020207004989A patent/KR20200031673A/ko not_active Ceased
- 2018-07-03 PL PL18740140T patent/PL3654932T3/pl unknown
- 2018-07-03 HR HRP20220034TT patent/HRP20220034T1/hr unknown
- 2018-07-03 RS RS20220029A patent/RS62825B1/sr unknown
-
2022
- 2022-01-10 CY CY20221100024T patent/CY1124904T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3654932T3 (da) | 2022-01-17 |
| CN111093611B (zh) | 2024-03-12 |
| CN111093611A (zh) | 2020-05-01 |
| SI3654932T1 (sl) | 2022-02-28 |
| HUE057646T2 (hu) | 2022-05-28 |
| CY1124904T1 (el) | 2023-01-05 |
| EP3654932A1 (de) | 2020-05-27 |
| KR20200031673A (ko) | 2020-03-24 |
| PT3654932T (pt) | 2022-01-24 |
| LT3654932T (lt) | 2022-01-10 |
| EP3654932B1 (de) | 2021-10-20 |
| RU2020107394A3 (enExample) | 2021-10-22 |
| WO2019015955A1 (de) | 2019-01-24 |
| MX2020000681A (es) | 2020-07-29 |
| HRP20220034T1 (hr) | 2022-04-01 |
| US20200139164A1 (en) | 2020-05-07 |
| JP2020528452A (ja) | 2020-09-24 |
| AU2018302367A1 (en) | 2020-02-20 |
| RU2020107394A (ru) | 2021-08-20 |
| PL3654932T3 (pl) | 2022-02-14 |
| AU2018302367B2 (en) | 2024-06-27 |
| JP7292272B2 (ja) | 2023-06-16 |
| SMT202200149T1 (it) | 2022-05-12 |
| RS62825B1 (sr) | 2022-02-28 |
| CA3070246A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2399738T3 (es) | Procedimiento y composición para el tratamiento de cicatrices | |
| ES3038299T3 (en) | Dermal skin protectant and carrier | |
| ES2904900T3 (es) | Tirotricina para usar en el tratamiento o la profilaxis del olor corporal, así como sus composiciones | |
| ES2684519T3 (es) | Composición dermatológica basada en extractos de algas y de hoja de olivo | |
| JP4808991B2 (ja) | 防臭フィルム製剤 | |
| Bhapkar et al. | Topic name–nail lacquers in nail diseases | |
| JP2020528452A5 (enExample) | ||
| Omura et al. | Dermatologic disorders of the foot | |
| JP2000212090A (ja) | 皮膚改質剤 | |
| RU2135161C1 (ru) | Композиция "рициниол" для лечения и косметического ухода за слизистыми оболочками, кожей и волосами | |
| US20040076694A1 (en) | Peppermint isopropyl alcohol | |
| US20130034618A1 (en) | Compositions for treating the integument | |
| Kontochristopoulos et al. | Managing pitted keratolysis: consider topical glycopyrrolate | |
| ES2672314A2 (es) | Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas | |
| US3514515A (en) | Method of controlling corns and callouses | |
| US9913807B2 (en) | Topical pharmaceutical bases for treating skin conditions | |
| Ahmad et al. | Superficial Dermatophytic Infection Prevention and Its Management: A Review | |
| Brandaleone et al. | PROPHYLACTIC FOOT TREATMENT IN PATIENTS WITH DIABETES MELLITUS: ANALYSES OF ITS EFFECT OF THE PREVENTION OF INFECTION OF THE LOWER EXTREMITIES AND THE OPERATIVE PROGNOSIS IN A SERIES OF FIVE HUNDRED SEVENTY-SIX CASES | |
| JP2000212053A (ja) | 皮膚保護消臭剤 | |
| US20060147408A1 (en) | Skin cleansing and sloughing solution | |
| BR102023026058A2 (pt) | Formulação cosmética e seu uso | |
| HK40020735B (en) | Tyrothricin for use in the treatment or prophylaxis of body odour and preparations therefor | |
| HK40020735A (en) | Tyrothricin for use in the treatment or prophylaxis of body odour and preparations therefor | |
| Rehbock | Common skin conditions that are treated by the podiatrist: clinical | |
| Basler | Skin conditions |